Benzinga | May 28, 2021 10:11AM EDT

Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $92

Mizuho analyst Vamil Divan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $90 to $92.